Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.34B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 9.92M
Average 4.07M
Dividends
Nuvation Bio Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Nuvation Bio Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Edgewise Therapeutics, Inc. NASDAQ:EWTX | $4.94B | 0.00% | $0.00 | 0.00% | 0.00% |
AbCellera Biologics Inc. NASDAQ:ABCL | $3.75B | 0.00% | $0.00 | 0.00% | 0.00% |
Viridian Therapeutics, Inc. NASDAQ:VRDN | $3.51B | 0.00% | $0.00 | 0.00% | 0.00% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | 0.00% | $0.00 | 0.00% | 0.00% |
Aurinia Pharmaceuticals Inc. NASDAQ:AUPH | $2.11B | 0.00% | $0.00 | 0.00% | 4.25% |
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | 0.00% | $0.00 | 0.00% | 0.00% |
uniQure N.V. NASDAQ:QURE | $1.67B | 0.00% | $0.00 | 0.00% | 0.00% |
Ocular Therapeutix, Inc. NASDAQ:OCUL | $1.37B | 0.00% | $0.00 | 0.00% | 0.00% |
Structure Therapeutics Inc. NASDAQ:GPCR | $1.15B | 0.00% | $0.00 | 0.00% | 0.00% |
Janux Therapeutics, Inc. NASDAQ:JANX | $695.66M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about NUVB's dividend, answered from reported figures.
Does NUVB stock pay dividends?
Nuvation Bio Inc. (NUVB) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is NUVB's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.